Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.

Address: Department of Urology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA. Electronic address: [email protected].; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX.; Carolina Urologic Research Center, Myrtle Beach, SC.; Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL.; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.; Department of Urology, Upstate Medical University, Syracuse, NY.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Division of Urology, University of Texas Medical Branch, Galveston, TX.; Department of Genitourinary Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; Department of Urology, Vanderbilt University Medical Center, Nashville, TN.; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.; Department of Urology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA.; Oncologic Urology Unit, Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain.; Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris Cité, Paris, France.; Department of Urology, Nara Medical University, Kashihara, Nara, Japan.; Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.; Janssen Research & Development, Lexington, MA.; Janssen Research & Development, Spring House, PA.; Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele University, Milan, Italy.